E3 PreliminaryPreliminaryPEM not requiredMechanisticPeer-reviewedMachine draft
Anti-stress effects of human placenta extract: possible involvement of the oxidative stress system in rats.
Park, Hyun-Jung, Shim, Hyun Soo, Lee, Sunyoung et al. · BMC complementary and alternative medicine · 2018 · DOI
Quick Summary
Researchers tested whether a supplement made from human placenta could help reduce stress-related depression and fatigue in rats. They found that rats treated with this supplement showed improvements in depression-like behaviors and had better antioxidant protection in their brains compared to untreated rats.
Why It Matters
ME/CFS patients frequently experience stress-related exacerbations and oxidative stress is implicated in disease pathophysiology. This study provides preliminary mechanistic evidence that compounds reducing oxidative stress and modulating stress-response pathways may have therapeutic potential, though human studies are essential before clinical application.
Observed Findings
- Rats treated with hPH showed significantly reduced immobility time in the forced swimming test (depression-like behavior marker) compared to controls.
- hPH treatment produced a modest decreasing trend in anxiety-like behavior on the elevated plus maze.
- hPH increased glutathione peroxidase protein levels in the hippocampus, a key brain region involved in mood and stress response.
- hPH decreased NADPH-diaphorase expression in the paraventricular nucleus, suggesting reduced nitric oxide synthase activity in stress-regulatory circuits.
Inferred Conclusions
- Human placenta hydrolysate exerts anti-stress effects through dual mechanisms: enhancing antioxidant defenses and modulating nitric oxide signaling in stress-responsive brain regions.
- The antioxidant and anti-inflammatory properties of hPH may underlie its effects on stress-induced depressive behaviors.
- hPH warrants further investigation as a potential therapeutic agent for stress-related conditions including chronic fatigue syndrome.
Remaining Questions
- Does hPH demonstrate similar efficacy and safety in humans with ME/CFS or other stress-related conditions?
- What are the specific bioactive compounds in hPH responsible for these effects, and what are optimal dosing and delivery routes for humans?
What This Study Does Not Prove
This rat study cannot establish that human placenta extract is safe or effective in ME/CFS patients; animal stress models do not fully replicate human disease complexity. The study demonstrates association between hPH treatment and biochemical changes, but does not prove these changes are causally responsible for behavioral improvements or would translate to clinical benefit in humans.
Tags
Symptom:Fatigue
Biomarker:Blood Biomarker
Method Flag:Small SampleExploratory Only
Metadata
- DOI
- 10.1186/s12906-018-2193-x
- PMID
- 29739458
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →